Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | Rethinking anti-protein therapies for neurodegenerative diseases

Alberto Espay, MD, MSc, University of Cincinnati, Cincinnati, OH, discusses recent developments in the treatment of neurodegenerative diseases. Most treatments under development for diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis target the proteins thought to be involved in the pathophysiology of the disease, including anti-amyloid- β, anti-tau, and anti-synuclein therapies. However, evidence suggests that targeting proteins does not give patients the best overall outcome or best risk-benefit, which highlights the importance of developing new therapies and approaches for neurodegenerative diseases. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr. Espay has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Neuroderm, Amneal, Acadia, Avion Pharmaceuticals, Acorda, Kyowa Kirin, Sunovion, Supernus (formerly, USWorldMeds), and Herantis Pharma; personal honoraria for speakership for Avion, Amneal, and Supernus; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He cofounded REGAIN Therapeutics and is co-inventor of the patent “Compositions and methods for treatment and/or prophylaxis of proteinopathies.” He serves on the editorial boards of the Journal of Parkinson’s Disease, Journal of Alzheimer’s Disease, European Journal of Neurology, Movement Disorders Clinical Practice, and JAMA Neurology.